|Bid||102.50 x 1100|
|Ask||103.30 x 1000|
|Day's range||100.97 - 104.74|
|52-week range||95.02 - 217.25|
|Beta (5Y monthly)||1.62|
|PE ratio (TTM)||34.43|
|Earnings date||01 Nov 2023 - 06 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||181.35|
Moderna (NASDAQ: MRNA) used to be a stock market star, climbing 1,700% from the start of 2020 through July of 2021. Investors liked that, and it clearly showed in the stock performance. After all, the vaccine is Moderna's only product right now, and demand for it has declined.
Once a relatively unknown biotech company, Moderna (NASDAQ: MRNA) became a household name when it became one of the first companies to offer a vaccine for the COVID-19 virus. At its peak, Moderna saw quarterly revenue of $7 billion as it sold vaccines to the world. Its stock price followed suit, reaching an all-time high of $484 in mid-2021.
CRISPR Therapeutics (NASDAQ: CRSP) specializes in gene editing, or the repair of faulty genes responsible for disease. Right now, CRISPR is heading for its biggest moment ever -- a regulatory decision on what may become its first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March.